BioCryst Pharmaceuticals | Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Alnylam Pharmaceuticals USD 1.49B 376.56M 2025-09
BioCryst Pharmaceuticals USD 84.08M 3.95M 2025-09
Chugai Pharma JPY 456.43B 40.66B 2025-09
Daiichi Sankyo JPY 542.16B 97.68B 2025-09
DBV Technologies USD 69.84M 33.37M 2025-09
Enanta Pharmaceuticals USD 32.3M 12.51M 2025-09
Gilead Sciences USD 7.33B 2.19B 2025-09
GlaxoSmithKline GBP 3.3B 303M 2025-09
Glaxosmithkline GBP 3.3B 303M 2025-09
Incyte USD 3.58B 650.78M 2025-12
Ionis Pharmaceuticals USD 2.24B 1.94B 2025-09
Karyopharm Therapeutics USD 37.67M 1.05M 2025-09
Neurocrine Biosciences USD 340.2M 76.2M 2025-09
Novavax USD 268.02M 14.28M 2025-09
PTC Therapeutics USD 672.62M 344.77M 2025-09
Regeneron Pharmaceuticals USD 18.87B 16.36B 2025-12
Roche Holding CHF 7.55B 579M 2025-06
Sarepta Therapeutics USD 613.08M 102.48M 2025-09
Ultragenyx Pharmaceutical USD 202.51M 36.4M 2025-09
Vertex Pharmaceuticals USD 6.29B 95.8M 2025-09


BioCryst Pharmaceuticals Srodki Pieniężne I Ekwiwalent - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Feb 2026.